Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib

Journal of Oncology Pharmacy Practice

Volumn 15, Issue 2, 2009, Pages 111-117

  Hogan, Thomas ^a   Yu, Jing Jie ^b   Williams, H James ^b   Altaha, Ramin ^a   Liang, Xiaobing ^b   He, Qi ^b  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Anaplastic; EGFR; Erlotinib; Exons 18 20; H rthle cell; Oncocytic; Thyroid cancer; TKI

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GENOMIC DNA; PROTEIN TYROSINE KINASE;

AGED; ANAPLASTIC CARCINOMA; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; FATALITY; FEMALE; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERMETABOLISM; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MUTATIONAL ANALYSIS; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CANCER;

AGED; CARCINOMA; FEMALE; HUMANS; POINT MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 68349090219     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155208101212     Document Type: Article

References (26)

1. Pasieka JL Anaplastic thyroid cancer. Current Opinion in Oncology 2003; 15(1): 78-83.
2. Chiu AC, Oliveira AA, Schultz PN, Ordonez NG, Sherman SI Prognostic clinicopathologic features in oncocytic neoplasia. Thyroid 1996; 6: S29.
3. Carcangiu ML, Steeper T., Zampi G., Rosai J. Anaplastic thyroid cancer: A study of 70 cases. Am J Clin Pathol 1985; 83(2): 135-58.
4. McIver B., Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB et al. Anaplastic thyroid cancer: A 50-year experience at a single institution. Surgery 2001; 130(6): 1028-34.
5. Nel CJ, van Heerden JA, Goellner JR, Gharib H., McConahey WM, Taylor WF et al. Anaplastic cancer of the thyroid: A clinicopathologic study of 82 cases. Mayo Clin Proc 1985; 60(1): 51-8.
6. Tan RK, Finley RK, Driscoll D., Bakamjian V., Hicks Jr WL, Shedd DP Anaplastic cancer of the thyroid: A 24-year experience. Head Neck 1995; 17(1): 41-7.
7. Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H., Samaan NA Anaplastic cancer of the thyroid: A clinicopathologic study of 121 cases. Cancer 1990; 66(2): 321-30.
8. Moore Jr JH, Bacharach B., Choi HY Anaplastic transformation of metastatic follicular cancer of the thyroid. J Surg Oncol 1985; 29(4): 216-21.
9. Nakamura T., Yana I., Kobayashi T., Shin E., Karakawa K., Fujita S. et al. p53 gene mutations associated with anaplastic transformation of human thyroid cancers. Jpn J Cancer Res 1992; 83(12): 1293-8.
10. Ito T., Seyama T., Mizuno T., Tsuyama N., Hayashi T., Hayashi Y. et al. Unique association of p53 mutations with undifferentiated but not with differentiated cancers of the thyroid gland. Cancer Res 1992; 52(5): 1369-71.
11. Ito T., Seyama T., Mizuno T., Tsuyama N., Hayashi Y., Dohi K. et al. Genetic alterations in thyroid tumor progression: Association with p53 gene mutations. Jpn J Cancer Res 1993; 84(5): 526-31.
12. Moretti F., Farsetti A., Soddu S., Misiti S., Crescenzi M., Filetti S. et al. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic cancer cells. Oncogene 1997; 14(6): 729-40.
13. Komoike Y., Tamaki Y., Sakita I., Tomita N., Ohue M., Sekimoto M. et al. Comparative genomic hybridization defines frequent loss on 16p in human anaplastic thyroid cancer. Int J Oncol 1999; 14(6): 1157-62.
14. Quiros RM, Ding HG, Gattuso P., Prinz RA, Xu X. Evidence that one subset of anaplastic thyroid cancers are derived from papillary cancers due to BRAF and p53 mutations. Cancer 2005; 103(11): 2261-8.
15. Arteaga C. Targeting HER1/EGFR: A molecular approach to cancer therapy. Semin Oncol 2003; 30(3 Suppl 7): 3-14.
16. Langer CJ Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: Focus on NSCLC. Int J Radiat Oncol Biol Phys 2004; 58(3): 991-1002.
17. Pao W., Miller VA Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005; 23: 2556-68.
18. Lynch TJ, Bell DW, Sordella R., Gurubhagavatula S., Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350(21): 2129-39.
19. Trotti A., Colevas AD, Setser A., Rusch V., Jaques D., Budach V. et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13(3): 176-81.
20. Nobuhara Y., Onoda N., Yamashita Y., Yamasaki M., Ogisawa K., Takashima T. et al. Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br J Cancer 2005; 92(6): 1110-6.
21. NCBI Database. http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=10251977 (accessed 2 January 2009)
22. Kimchi-Sarfaty C., Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV et al. A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315(5811): 525-8.
23. Bernig T., Boersma BJ, Howe TM, Welch R., Yadavalli S., Staats B. et al. The mannose-binding lectin (MBL2) haplotype and breast cancer: An association study in African-American and Caucasian women. Carcinogenesis 2007; 28: 828-36.
24. DeLellis RA, LLoyd R, Heitz PU, eds. WHO classification of tumors, pathology and genetics-tumors of endocrine organs. Lyon: IARC Press, 2004.
25. Volante M., Landolfi S., Chiusa L., Palestini N., Motta M., Codegone A. et al. Poorly differentiated cancers of the thyroid with trabecular, insular and solid patterns. A clinico-pathological study of 183 cases. Cancer 2004; 100(5): 950-7.
26. Volante M., Collini P., Nikiforov YE, Sakamoto A., Kakudo K., Katoh R. et al. Poorly differentiated thyroid cancer: The turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 2007; 31(8): 1256-64.